Greyzone myocardial fibrosis and ventricular arrhythmias in patients with a left ventricular ejection fraction >35%

Abstract

AIMS: To determine whether myocardial fibrosis and greyzone fibrosis (GZF) on cardiovascular magnetic resonance (CMR) is associated with ventricular arrhythmias in patients with coronary artery disease (CAD) and a left ventricular ejection fraction (LVEF) >35%. METHODS AND RESULTS: In this retrospective study of CAD patients, GZF mass using the 3SD method (GZF3SD) and total fibrosis mass using the 2SD method (TF2SD) on CMR were assessed in relation to the primary, combined endpoint of sudden cardiac death, ventricular tachycardia, ventricular fibrillation, or resuscitated cardiac arrest. Among 701 patients [age: 65.8 ± 12.3 years (mean ± SD)], 28 (3.99%) patients met the primary endpoint over 5.91 years (median; interquartile range 4.42-7.64). In competing risks analysis, a GZF3SD mass ≥5.0 g was strongly associated with the primary endpoint [subdistribution hazard ratio (sHR): 17.4 (95% confidence interval, CI 6.64-45.5); area under receiver operator characteristic curve (AUC): 0.85, P < 0.001]. A weaker association was observed for TF2SD mass ≥23 g [sHR 10.4 (95% CI 4.22-25.8); AUC: 0.80, P < 0.001]. The range of sHRs for GZF3SD mass (1-527) was wider than for TF2SD mass (1-37.6). CONCLUSIONS: In CAD patients with an LVEF >35%, GZF3SD mass was strongly associated with the arrhythmic endpoint. These findings hold promise for its use in identifying patients with CAD and an LVEF >35% at risk of arrhythmic events.

Publication DOI: https://doi.org/10.1093/europace/euab167
Divisions: College of Health & Life Sciences > Aston Medical School
College of Health & Life Sciences
College of Health & Life Sciences > School of Biosciences
College of Health & Life Sciences > Aston Medical School > Translational Medicine Research Group (TMRG)
Additional Information: © The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com Funding: We are grateful to Medtronic Plc and Boston Scientific for their support in funding this study, in the form of unrestricted educational grants.
Uncontrolled Keywords: Cardiovascular magnetic resonance,Coronary artery disease,Greyzone scar,Myocardial fibrosis,Sudden cardiac death,Ventricular fibrillation,Ventricular tachycardia,Cardiology and Cardiovascular Medicine,Physiology (medical)
Publication ISSN: 1532-2092
Last Modified: 02 Oct 2024 16:43
Date Deposited: 24 Nov 2021 17:56
Full Text Link:
Related URLs: https://academi ... edFrom=fulltext (Publisher URL)
http://www.scop ... tnerID=8YFLogxK (Scopus URL)
PURE Output Type: Article
Published Date: 2022-01-04
Published Online Date: 2021-08-11
Accepted Date: 2021-06-13
Authors: Zegard, Abbasin
Okafor, Osita
de Bono, Joseph
Kalla, Manish
Lencioni, Mauro
Marshall, Howard
Hudsmith, Lucy
Qiu, Tian
Steeds, Richard
Stegemann, Berthold (ORCID Profile 0000-0003-2841-8022)
Leyva-Leon, Francisco

Download

Export / Share Citation


Statistics

Additional statistics for this record